Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program.
Lineage, Inc. (LINE) Q2 2026 Earnings Call Transcript
Lineage NASDAQ: LINE reported second-quarter results that exceeded its internal expectations and consensus estimates as warehouse occupancy improved and cost-control efforts helped offset continued trade-related volume pressure.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Curtis Ellergodt Rothschild Investment LLC | 4,358 | $145,345.17 | $182,839.89 | $37,494.72 | 25.8% |
| MN Marcia Nakamura Fairview Capital Investment Management LLC | 799,518 | $38.72M | $33.38M | -$5.34M | -13.79% |
| GVY George V. Young VILLERE ST DENIS J & Co. LLC | 618,495 | $31.07M | $26.2M | -$4.87M | -15.68% |
| JM John Malone Amundi | 41,081 | $3M | $1.7M | -$1.3M | -43.29% |
Mina Iskander Darlington Partners Capital Management LP | 1.53M | $52.42M | $64.04M | $11.61M | 22.15% |
| Industrial REITs Industry | Real Estate Sector | W. Gregory Lehmkuhl CEO | NASDAQ (NGS) Exchange | 53566V106 CUSIP |
| US Country | 24,000 Employees | 30 Jun 2026 Last Dividend | - Last Split | - IPO Date |
Lineage, Inc., a subsidiary of BG Lineage Holdings, LLC, stands as the largest global warehouse real estate investment trust (REIT) specializing in temperature-controlled spaces. Our real estate portfolio, as of March 31, 2024, boasts over 84.1 million square feet (3.0 billion cubic feet of capacity) across 482 warehouses. These strategically located properties span across critical distribution markets with 312 in North America, 82 in Europe, and 88 in Asia-Pacific. Our client base is expansive and diverse, including over 13,000 customers ranging from the biggest names in food retailing, manufacturing, processing, and distribution. Financial performance for the quarter ending March 31, 2024, revealed $1.3 billion in revenue and a net loss of $48.0 million. For the fiscal year 2023, the company achieved $5.3 billion in revenue, with a net loss of $96.2 million. These figures underscore our firm's pivotal role in the global temperature-controlled supply chain, offering unparalleled and technologically advanced solutions to a myriad of customer requirements.
Our portfolio of products and services is designed to meet the diverse and intricate needs of the temperature-controlled supply chain. Each offering is underpinned by our vast global network and cutting-edge technology, ensuring seamless and efficient logistics solutions.